Recombinant Proteins Market Share, Growth, Trends and Scope 2022-2030

Recombinant Proteins Market Size, Share & Trends Analysis By Product, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Recombinant Proteins Market Size, Share & Trends Analysis By Product, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Published: Mar 2022 Report ID: BIOT2208 Pages: 1 - 236 Formats*:     
Category : Biotechnology
Global Recombinant Proteins Market Overview:

According to SPER Market Research, the recombinant proteins market estimated to reach USD 2.4 billion by 2030 with a CAGR of 10.2%. The fuels for the escalation of the market are; the collaboration of industry and academia, expiring of patents of biologic product, growing investments from the government in the pharmaceutical and bio pharmaceutical research and development.

Impact of COVID-19 on the Recombinant Proteins Market 
The outbreak of COVID-19 gave an upsurge to the Recombinant Proteins Market; this is due to increase in research and development to reach out the cause of the infection. Companies with product for COVID-19 have a positive expansion.

Scope of the report:
 Report Metric Details
 Market size available for years 2019-2030
 Base year considered 2021
 Forecast period 2022-2030
 Segments coveredBy Product, By Application, By End-User, By Region
 Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
 Companies CoveredAbcam plc, Abnova Corporation, ACRO Biosystems, Aviva Systems Biology Corporation, Biolegend, Bio-Rad Laboratories, Inc. , Biotech Corporation, BPS Bioscience, Inc., CellGenix GmbH, Enzo Life Sciences, Inc., GenScript, Icosagen AS, Merck KGaA, Miltenyi Biotech, Neuromics, PeproTech, Inc., ProSpec TechnoGene Ltd., Proteintech Group, Inc., ProteoGenix, R&D Systems, RayBiotech Inc, RICHCORE LIFESCIENCES PVT LTD, Sino Biological Inc., STEMCELL Technologies Inc, StressMarq Biosciences Inc, Thermo Fisher Scientific, Inc.,  United States Biological.

Drivers: increasing government funding and growing Research & Development costs in pharmaceutical & biotechnology companies 
Government funding, growing pharmaceutical and biopharmaceuticals research and development are the key factors that drive the escalation of the market.

Restraints: declining price of recombinant Protein
Due to concentration of various market players in the production of recombinant Protein with no varying price; this lead to resist the escalation of the market.

Opportunity: Emerging Economies
Emerging Economies, like Asia Pacific is projected to tender huge opportunities for the players in this market; this is due to rising prevalence of infectious chronic disease, multiple healthcare sector, growing government funding in the research and development of the advanced techniques in proteomic and genomic research, increasing geriatric population, friendly regulatory policies.

Global Recombinant Proteins Market Segmentation:

By Product: Based on the Product, Global Recombinant Proteins Market is segmented as; Adhesion Molecules and Receptors, Growth Factors and Chemokines, Immune Response Proteins, Kinase Proteins, Membrane Proteins, Recombinant Metabolic Enzymes, Regulatory Proteins, Structural Proteins, Other Recombinant Proteins.

By Application: Based on the Application, Global Recombinant Proteins Market is segmented as; Drug Discovery & Development (Biologics, Cell & Gene Therapy, Vaccines), Biopharmaceutical Production, Biotechnology Research, Academic Research Studies, Other Applications (diagnostics, forensic, and cosmetology applications).

By End-User: Based on the End-User, Global Recombinant Proteins Market is segmented as; Academic Research Institutes, Biotechnology Companies, Contract Research Organizations, Pharmaceutical & Biopharmaceutical Companies, Other End Users [diagnostic centers, laboratories (hospital-attached laboratories (HALs) and independent diagnostic laboratories), forensic laboratories, and the cosmetic industry].

By Region: North America owns the prime share of the market; and this is due to the presence of top market players, government funding, growing prevalence of infectious and chronic diseases, growing research and development.

1. Introduction
1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges 
4.2. COVID-19 Impacts of the Recombinant Proteins Market

5. Market variables and outlook
5.1. SWOT analysis 
5.1.1 Strengths 
5.1.2 Weaknesses 
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis 
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape 
5.2.4 Technological landscape 
5.2.5 Environmental landscape 
5.2.6 Legal landscape 
5.3. PORTER’S five forces analysis 
5.3.1 Bargaining power of suppliers 
5.3.2 Bargaining power of Buyers 
5.3.3 Threat of Substitute 
5.3.4 Threat of new entrant 
5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Recombinant Proteins Market, By Product, 2019-2030 (USD Million)
6.1. Adhesion Molecules and Receptors
6.2. Growth Factors and Chemokines
6.3. Immune Response Proteins
6.4. Kinase Proteins
6.5. Membrane Proteins
6.6. Recombinant Metabolic Enzymes
6.7. Regulatory Proteins
6.8. Structural Proteins
6.9. Other Recombinant Proteins

7. Global Recombinant Proteins Market, By Application, 2019-2030 (USD Million)
7.1. Drug Discovery & Development
7.1.1. Biologics
7.1.2. Cell & Gene Therapy
7.1.3. Vaccines
7.2. Biopharmaceutical Production
7.3. Biotechnology Research
7.4. Academic Research Studies
7.5. Other Applications (diagnostics, forensic, and cosmetology applications)

8. Global Recombinant Proteins Market, By End-User, 2019-2030 (USD Million)
8.1. Academic Research Institutes
8.2. Biotechnology Companies
8.3. Contract Research Organizations
8.4. Pharmaceutical & Biopharmaceutical Companies
8.5. Other End Users [diagnostic centers, laboratories (hospital-attached laboratories (HALs) and independent diagnostic laboratories), forensic laboratories, and the cosmetic industry]

9. Global Recombinant Proteins Market, By Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia 
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa

10. Company Profiles
10.1. Abcam plc 
10.1.1. Company details 
10.1.2. Financial outlook
10.1.3. Product summary 
10.1.4. Recent developments
10.2. Abnova Corporation 
10.2.1. Company details 
10.2.2. Financial outlook
10.2.3. Product summary 
10.2.4. Recent developments
10.3. ACRO Biosystems
10.3.1. Company details 
10.3.2. Financial outlook
10.3.3. Product summary 
10.3.4. Recent developments
10.4. Aviva Systems Biology Corporation 
10.4.1. Company details 
10.4.2. Financial outlook
10.4.3. Product summary 
10.4.4. Recent developments
10.5. Biolegend 
10.5.1. Company details 
10.5.2. Financial outlook
10.5.3. Product summary 
10.5.4. Recent developments
10.6. Bio-Rad Laboratories, Inc.
10.6.1. Company details 
10.6.2. Financial outlook
10.6.3. Product summary 
10.6.4. Recent developments
10.7. Biotech Corporation 
10.7.1. Company details 
10.7.2. Financial outlook
10.7.3. Product summary 
10.7.4. Recent developments
10.8. BPS Bioscience, Inc. 
10.8.1. Company details 
10.8.2. Financial outlook
10.8.3. Product summary 
10.8.4. Recent developments
10.9. CellGenix GmbH 
10.9.1. Company details 
10.9.2. Financial outlook
10.9.3. Product summary 
10.9.4. Recent developments
10.10. Enzo Life Sciences, Inc. 
10.10.1. Company details 
10.10.2. Financial outlook
10.10.3. Product summary 
10.10.4. Recent developments
10.11. GenScript 
10.11.1 Company details 
10.11.2 Financial outlook
10.11.3 Product summary 
10.11.4 Recent developments
10.12. Icosagen AS 
10.12.1. Company details 
10.12.2. Financial outlook
10.12.3. Product summary 
10.12.4. Recent developments
10.13. Merck KGaA 
10.13.1. Company details 
10.13.2. Financial outlook
10.13.3. Product summary 
10.13.4. Recent developments
10.14. Miltenyi Biotech
10.14.1. Company details 
10.14.2. Financial outlook
10.14.3. Product summary 
10.14.4. Recent developments
10.15. Neuromics 
10.15.1. Company details 
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. PeproTech, Inc. 
10.16.1. Company details 
10.16.2. Financial outlook
10.16.3. Product summary 
10.16.4. Recent developments
10.17. ProSpec TechnoGene Ltd. 
10.17.1. Company details 
10.17.2. Financial outlook
10.17.3. Product summary 
10.17.4. Recent developments
10.18. Proteintech Group, Inc. 
10.18.1. Company details 
10.18.2. Financial outlook
10.18.3. Product summary 
10.18.4. Recent developments
10.19. ProteoGenix 
10.19.1. Company details 
10.19.2. Financial outlook
10.19.3. Product summary 
10.19.4. Recent developments
10.20. R&D Systems 
10.20.1. Company details 
10.20.2. Financial outlook
10.20.3. Product summary 
10.20.4. Recent developments
10.21. RayBiotech Inc.
10.21.1. Company details 
10.21.2. Financial outlook
10.21.3. Product summary 
10.21.4. Recent developments
10.22. Richcore Lifesciences Pvt Ltd 
10.22.1. Company details 
10.22.2. Financial outlook
10.22.3. Product summary 
10.22.4. Recent developments
10.23. Sino Biological Inc. 
10.23.1. Company details 
10.23.2. Financial outlook
10.23.3. Product summary 
10.23.4. Recent developments
10.24. STEMCELL Technologies Inc 
10.24.1. Company details 
10.24.2. Financial outlook
10.24.3. Product summary 
10.24.4. Recent developments
10.25. StressMarq Biosciences Inc 
10.25.1. Company details 
10.25.2. Financial outlook
10.25.3. Product summary 
10.25.4. Recent developments
10.26. Thermo Fisher Scientific, Inc.
10.26.1. Company details 
10.26.2. Financial outlook
10.26.3. Product summary 
10.26.4. Recent developments
10.27. United States Biological 
10.27.1. Company details 
10.27.2. Financial outlook
10.27.3. Product summary 
10.27.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings.  The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.




Not able to find what you are looking for? Need customization in the existing report?
Click Here
  • 15% off
    $ 4250
  • 20% off
    $ 5650
  • 25% off
    $ 7450
Pre-Purchase Inquiry
Request Customization
100% Secure Payment

SPER American Express
SPER Master Card
SPER Mestro
SPER Paypal
SPER CCAvenues

Join Our SPER Panel

Our Global Clients

Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Johnson & Johnson
SPER-Astellas Pharma
SPER-Citi Bank
SPER-Johnson & Johnson


Market Research

We are the leading, full-service global market research and consulting company.

iso-1 iso-1
Secure Payments
SPER Payment Options
Connect with us